3.2 Target Audience Identification: HCPs, Patients, Payers & Regulators
Key Takeaways
Strategic audience segmentation aligns clinical evidence delivery with the divergent decision-making needs of subspecialists, primary care providers, multidisciplinary healthcare teams, payers, patients, and health authorities.
Health Economics and Outcomes Research (HEOR) publications communicate QALYs, ICERs, budget impact models, and patient-reported outcomes (PROs) required by Health Technology Assessment (HTA) bodies and formulary committees.
Plain Language Summaries translate research into audience-appropriate language, preserve balanced benefits, harms, uncertainty, and funding disclosure, and should be tested with intended readers where feasible.
Clinical Study Reports (CSRs) fulfill exhaustive technical regulatory disclosure obligations, whereas peer-reviewed manuscripts deliver concise, clinically contextualized interpretations for medical practice.
Publication planning must systematically map specific publication types (primary efficacy, secondary analyses, sub-studies, reviews, letters) to targeted audience workflows and compliance boundaries.
3.2 Target Audience Identification: HCPs, Patients, Payers & Regulators
Quick Answer: Strategic audience segmentation ensures that clinical trial evidence is translated and delivered in formats appropriate for distinct stakeholder groups—including subspecialists, primary care providers, allied healthcare professionals, payers, patients, and regulatory bodies. Each audience possesses distinct information requirements, varying health literacy levels, and specific regulatory constraints. Effective publication plans map primary manuscripts, secondary analyses, HEOR models, plain language summaries (PLS), and regulatory summaries to these targeted constituencies.
Principles of Audience Segmentation in Medical Publication Planning
Clinical trial data do not exist in a vacuum; their ultimate utility depends on how effectively findings are communicated to the individuals who make treatment, reimbursement, and policy decisions. In publication planning, audience segmentation is the systematic process of identifying, categorizing, and prioritizing target stakeholder groups to determine the optimal timing, format, scientific depth, and venue for disseminating study results.
A common pitfall in publication management is adopting a "one-size-fits-all" approach—such as assuming that a single primary efficacy paper in a high-impact general medical journal satisfies all scientific communication needs. In reality, different audiences require distinct evidence packages to make informed decisions:
- A tertiary subspecialist requires granular molecular mechanisms, subgroup survival curves, and biomarker stratification data.
- A community physician requires clear diagnostic thresholds, comparative safety profiles against common alternatives, and practical patient selection criteria.
- A clinical oncology nurse requires premedication protocols, infusion schedules, early toxicity recognition guides, and patient counseling strategies.
- A hospital pharmacy director or formulary committee requires head-to-head comparative effectiveness data, drug stability details, and institutional cost impacts.
- A health economist or reimbursement authority requires cost-utility analyses, Quality-Adjusted Life Years (QALYs), and budget impact projections.
- A patient or caregiver requires clear explanations of potential benefits, symptom relief, daily functional impacts, administration burden, and common side effects, presented in non-technical language.
Strategic publication planning constructs an evidence dissemination matrix that sequences deliverables across the asset lifecycle to meet each audience's distinct requirements without violating ethical standards regarding redundant or premature publication.
+-----------------------------------------------------------------------------------+
| THE MEDICAL PUBLICATION AUDIENCE SPECTRUM |
+-----------------------------------------------------------------------------------+
| HEALTHCARE PROFESSIONALS | ECONOMIC & POLICY | PATIENT COMMUNITY |
| - Tertiary Subspecialists | - HTA Bodies (NICE, IQWiG| - Diagnosed Patients |
| - General Practitioners | - Commercial Payers / PBM| - Family Caregivers |
| - Clinical Pharmacists | - Hospital P&T Committees| - Patient Advocates |
| - Specialized Nurses | - Regulatory Reviewers | - Lay Public |
+-----------------------------------------------------------------------------------+
Healthcare Professional (HCP) Stratification: Subspecialists, Generalists, and Allied Health
When tailoring scientific publications for healthcare practitioners, publication professionals must evaluate the clinical workflow and decision-making context of each clinician subgroup:
Subspecialists vs. Primary Care Physicians (PCPs)
Subspecialists (e.g., medical oncologists, interventional cardiologists, rheumatologists) represent the initial target audience for specialty therapeutics. They read specialized, organ-specific journals (e.g., Journal of Clinical Oncology, Circulation) and attend international society congresses (e.g., ASCO, ESMO, AHA). Subspecialists demand rigorous biostatistical methodology, detailed pharmacodynamic and pharmacokinetic (PK/PD) sub-studies, exploratory biomarker correlations, and mechanistic rationale.
In contrast, primary care physicians (PCPs) and general internists treat multi-morbid patient populations and manage care across multiple therapeutic areas. They read broad general medical journals (e.g., NEJM, Lancet, JAMA, Annals of Internal Medicine, American Family Physician). PCPs need publications that emphasize:
- Clear disease identification criteria and validated screening algorithms.
- Pragmatic safety warnings, routine laboratory monitoring intervals, and drug-drug interactions with common chronic medications (e.g., statins, antihypertensives).
- Clear guidelines on when to initiate therapy versus when to refer to tertiary specialty care.
Multidisciplinary Allied Health: Nurses and Clinical Pharmacists
Modern patient care is delivered by multidisciplinary teams. Publication plans that neglect nurses and pharmacists fail to support real-world patient safety and adherence:
- Specialty Nurses and Nurse Practitioners (NPs): Nurses manage hands-on drug administration, patient education, and early detection of adverse events. Nursing-focused publications (e.g., Clinical Journal of Oncology Nursing) emphasize practical administration guidelines, extravasation management, infusion reaction protocols, toxicity grading, and supportive care strategies.
- Clinical Pharmacists and Formulary Managers: Clinical pharmacists are essential members of hospital Pharmacy and Therapeutics (P&T) committees. They evaluate publications in specialized pharmacotherapy journals (e.g., Pharmacotherapy, Journal of Managed Care & Specialty Pharmacy) focusing on product reconstitution, cold-chain storage stability, therapeutic drug monitoring, renal/hepatic dosing adjustments, and pharmacokinetic interactions.
Payer and Health Technology Assessment (HTA) Audiences: HEOR and Economic Value
Achieving regulatory approval does not guarantee patient access; a therapy must also achieve market access, reimbursement, and favorable formulary placement. Payers, reimbursement authorities, and Health Technology Assessment (HTA) agencies evaluate evidence through the lens of comparative clinical value, cost-effectiveness, and population health impact.
Key HEOR Disciplines and Metrics
Publication plans must incorporate dedicated Health Economics and Outcomes Research (HEOR) publications designed to address reimbursement hurdles:
- Cost-Utility Analysis (CUA): Measures the cost per Quality-Adjusted Life Year (QALY) or Disability-Adjusted Life Year (DALY) gained.
- Incremental Cost-Effectiveness Ratio (ICER): Evaluates the economic difference between the new intervention and the standard of care relative to their difference in clinical efficacy, calculated as the incremental cost divided by the incremental clinical benefit.
- Budget Impact Models (BIMs): Calculate the net financial impact on a specific healthcare plan, national health system, or hospital budget over a 1- to 5-year time horizon.
- Patient-Reported Outcomes (PROs) and Quality of Life (QoL): Validated instruments (e.g., EuroQol EQ-5D, SF-36, EORTC QLQ-C30) quantify how an intervention impacts physical functioning, pain, mental well-being, and daily independence.
Navigating Global HTA Requirements
HTA bodies across major global jurisdictions operate under differing statutory frameworks and valuation criteria:
- United Kingdom (NICE): Focuses rigorously on cost per QALY gained, typically enforcing a cost-effectiveness threshold of £20,000 to £30,000 per QALY.
- Germany (G-BA / IQWiG via AMNOG): Evaluates additional clinical benefit (Zusatznutzen) strictly against an appropriate comparative therapy (ACT), placing high evidentiary demands on direct head-to-head randomized trials rather than indirect comparisons.
- United States (ICER - Institute for Clinical and Economic Review): An independent academic research organization that models value-based price benchmarks and budget impact thresholds for commercial and public payers.
- Canada (CADTH / pCODR) and Australia (PBAC): Rigorous national cost-effectiveness and clinical utility reviews that directly determine inclusion on public provincial/federal drug formularies.
Note
HEOR and PRO publications must follow rigorous reporting guidelines just like clinical trials. Cost-effectiveness studies must comply with the CHEERS 2022 (Consolidated Health Economic Evaluation Reporting Standards) statement, while PRO data should be reported using the CONSORT-PRO extension.
Patient and Caregiver Audiences: The Ethical Mandate for Accessibility
Historically, biomedical publications were written exclusively by researchers for researchers, locking vital health discoveries behind paywalls and dense academic jargon. Over the past decade, a major paradigm shift led by patient advocacy groups, professional bodies, and progressive medical journals has established that patients have a fundamental ethical right to understand research derived from their clinical trial participation.
Plain Language Summaries (PLS)
A Plain Language Summary (PLS) is an objective, non-promotional summary of a scientific publication written specifically for non-specialists, including patients, family caregivers, patient advocates, and non-specialist clinicians.
Under GPP 2022 and professional PLS guidance:
- Target Readability: Plain language text should be calibrated to a audience-appropriate reading level (using validated readability metrics such as the Flesch-Kincaid Grade Level or Coleman-Liau Index).
- Core Formats: PLS can be published as:
- Embedded PLS: A dedicated plain-language abstract published within the primary manuscript alongside the traditional medical abstract.
- Standalone Plain Language Summary of Publication (PLSP): A separate, peer-reviewed, citable article published in an open-access journal.
- Visual / Infographic PLS: Graphical summaries depicting trial design, key results, and safety in accessible, visual layouts.
- Audio/Video PLS: Digital author narrations explaining study context and outcomes.
- Non-Promotional Standards: PLS must never function as marketing or promotional collateral. They must objectively balance efficacy benefits with adverse events and risks, disclose trial funding, and state that patients should consult their personal healthcare provider regarding medical decisions.
Tip
Best practice in PLS development involves partnering directly with patient co-authors or patient advocacy representatives during drafting. Patient contributors review text for clarity, tone, and clinical relevance to ensure that the patient perspective is authentic and accessible.
Regulatory Authorities and Public Disclosure: CSRs vs. Peer-Reviewed Manuscripts
A critical responsibility of the publication professional is managing the intersection between mandatory regulatory disclosures and voluntary peer-reviewed journal publications. While both communicate clinical trial data, they serve fundamentally different legal, operational, and clinical purposes.
| Dimension | Clinical Study Report (CSR) | Peer-Reviewed Manuscript |
|---|---|---|
| Primary Purpose | Regulatory approval and statutory compliance | Peer education, clinical dialogue, and scientific debate |
| Target Audience | Regulatory agency reviewers (FDA, EMA, PMDA, NMPA) | Practicing physicians, researchers, and clinicians |
| Document Length | Hundreds to thousands of pages (including appendices) | Typically 3,000 to 4,500 words |
| Level of Detail | Exhaustive individual patient listings, CRFs, SAS code | Synthesized summary statistics, key figures, and tables |
| Contextual Discussion | Factual, regulatory-focused; minimal external context | Broad contextualization within existing literature |
| Peer Review Mechanism | Reviewed by regulatory scientific assessment teams | Independent, blinded or open academic peer review |
| Public Availability | Redacted disclosure via clinical registries (CTIS/EMA) | Indexing in MEDLINE/PubMed, journal website access |
Disclosure Coordination: ClinicalTrials.gov, EU CTR, and the ICMJE Rule
Under statutory mandates such as FDAAA 801 in the United States and the EU Clinical Trials Regulation (EU CTR 536/2014) operating via the Clinical Trials Information System (CTIS) in Europe, clinical trial sponsors are legally obligated to post tabular summary results to public registries within 12 months of the Primary Completion Date (PCD).
Historically, authors feared that posting tabular trial results to ClinicalTrials.gov or CTIS would violate the "Ingelfinger Rule" (the journal policy prohibiting prior publication or duplicate submission). The ICMJE has explicitly clarified that:
- Posting required tabular results, protocol summaries, and brief safety data to a recognized public clinical trial registry within statutory deadlines does not constitute prior publication.
- Medical journal editors will not reject manuscripts based on timely registry disclosure required by law.
- Authors must cite the clinical trial registration number (e.g., NCT identifier) in all manuscript drafts and abstracts.
Strategic Evidence Mapping: Aligning Publication Types with Stakeholder Needs
To prevent disjointed publication activities, publication professionals develop a comprehensive delivery matrix mapping publication formats to target stakeholders and regulatory constraints:
| Publication Format | Target Stakeholder Audience | Core Content Focus | Key Regulatory / Governance Boundary |
|---|---|---|---|
| Primary Efficacy MS | Subspecialists, general practitioners, regulatory bodies | Primary/secondary endpoints, overall safety, methodology | Must report prespecified protocol endpoints objectively |
| Secondary / Subgroup MS | Subspecialists, academic clinical researchers | Stratified efficacy, biomarker correlations, long-term | Must clearly label post-hoc or exploratory analyses |
| HEOR / Cost-Utility MS | Payers, HTA reviewers (NICE, IQWiG), P&T committees | QALYs, ICERs, budget impact, real-world resource use | Adherence to CHEERS 2022 guidelines; no unsubstantiated |
| Plain Language Summary | Patients, caregivers, patient advocacy organizations | Non-technical summary of trial results and safety | 6th-8th grade readability; strictly non-promotional |
| Clinical Review Article | General practitioners, trainees, community clinicians | Disease landscape, treatment algorithms, clinical trials | Must declare all author COIs and commercial funding |
| Congress Abstract/Poster | Active conference delegates, specialist researchers | Rapid, preliminary, or updated trial efficacy/safety | Strict adherence to congress embargo and encore rules |
A pharmaceutical sponsor completes a Phase III trial evaluating a novel biologic for severe rheumatoid arthritis. In addition to primary disease activity scores, the trial collected detailed EuroQol EQ-5D data, direct hospital admission records, and work productivity loss metrics. Which publication vehicle and audience mapping is most appropriate for disseminating these specific economic and quality-of-life findings?
A rapid letter to the editor in a primary care journal highlighting drug pricing discounts.
A dedicated Health Economics and Outcomes Research (HEOR) manuscript submitted to a pharmacoeconomics journal, adhering to CHEERS reporting guidelines, targeting payers and HTA bodies.
An un-blinded marketing brochure distributed directly to hospital formulary managers prior to regulatory approval.
A digital video abstract hosted exclusively on the sponsor's corporate commercial website.
A publication team is developing a standalone Plain Language Summary of Publication (PLSP) to accompany a pivotal oncology trial paper. Which combination of design, language, and governance standards must be applied to ensure compliance with GPP 2022 and ISMPP guidance?
Target a graduate reading level, include promotional brand slogans, and exclude adverse event data to minimize patient anxiety.
Restrict distribution solely to certified oncologists, omitting patient advocates from the review process.
Publish the summary behind an institutional paywall to protect proprietary pharmaceutical trade secrets.
Use audience-appropriate language tested with intended readers where feasible, present balanced benefits, harms, and uncertainty without promotion, and follow the venue requirements.
A US Applicable Clinical Trial has a primary completion date of January 15, 2025, and its results are generally due on ClinicalTrials.gov one year later. The authors expect to submit the manuscript after that date. How does qualifying registry disclosure affect journal consideration under ICMJE policy?
ICMJE does not treat qualifying brief structured registry results or tables as prior publication, so the team should meet the applicable disclosure deadline and inform the journal.
The registry disclosure violates the Ingelfinger Rule, causing all major medical journals to automatically reject the primary manuscript.
The authors must withhold registry results until after the peer-reviewed manuscript is formally accepted and published.
The sponsor must obtain a written copyright waiver from the target journal editor before posting data to ClinicalTrials.gov.
Sections you finish are checked off in the contents.